Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne F Jones

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Investigational New Drugs|September 4, 2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumorsSuzanne F Jones, Lillian L Siu, Johanna C Bendell, et al.
The Oncologist|August 18, 2019
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE TrialDavid R Spigel, Dianna L Shipley, David M Waterhouse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignanciesGlen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2013
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancerJohanna C Bendell, Michael S Gordon, Herbert I Hurwitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerAnna Maria Storniolo, Mark D Pegram, Beth Overmoyer, et al.
Targeted Oncology|November 2, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib TrialErika P Hamilton, Gerald S Falchook, Judy S Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasHoward A Burris, Herbert I Hurwitz, E Claire Dees, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2016
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancerShubham Pant, Suzanne F Jones, Carla D Kurkjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosingPaula M Fracasso, Howard Burris, Matthew A Arquette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsKwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Investigational New Drugs|September 4, 2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumorsSuzanne F Jones, Lillian L Siu, Johanna C Bendell, et al.
The Oncologist|August 18, 2019
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE TrialDavid R Spigel, Dianna L Shipley, David M Waterhouse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignanciesGlen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2013
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancerJohanna C Bendell, Michael S Gordon, Herbert I Hurwitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2008
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerAnna Maria Storniolo, Mark D Pegram, Beth Overmoyer, et al.
Targeted Oncology|November 2, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib TrialErika P Hamilton, Gerald S Falchook, Judy S Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasHoward A Burris, Herbert I Hurwitz, E Claire Dees, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2016
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancerShubham Pant, Suzanne F Jones, Carla D Kurkjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosingPaula M Fracasso, Howard Burris, Matthew A Arquette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsKwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.
Pageof 7